"Oxford BioMedica, one of Britain’s oldest biotech companies, has concluded a $842m deal with Axovant Sciences of the US to commercialise its gene therapy for Parkinson’s disease.
Axovant Sciences will fund all clinical and manufacturing development costs for the product, which will be called AXO-Lenti-PD.
The deal will accelerate the clinical testing of Oxford BioMedica’s Parkinson’s disease gene therapy, which started about ten years ago."
Slow progress! Has to be an expensive therapy if it passes Phase III; early results sound hopeful